CrossRef Text and Data Mining

Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.

Concurrent and Adjuvant Temozolomide for Newly Diagnosed Grade III Gliomas without 1p/19q Co-deletion: A Randomized, Open-Label, Phase 2 Study (KNOG-1101 Study)

Kihwan Hwang, Tae Min Kim, Chul-Kee Park, Jong Hee Chang, Tae-Young Jung, Jin Hee Kim, Do-Hyun Nam, Se-Hyuk Kim, Heon Yoo, Yong-Kil Hong, Eun-Young Kim, Dong-Eun Lee, Jungnam Joo, Yu Jung Kim, Gheeyoung Choe, Byung Se Choi, Seok-Gu Kang, Jeong Hoon Kim, Chae-Yong Kim

Cancer Research and Treatment. 2020;52(2):505-515. Published online 2019 October 28 DOI: https://doi.org/10.4143/crt.2019.421

ACTR-50. EFFECT OF CONCURRENT AND ADJUVANT TEMOZOLOMIDE ON SURVIVAL IN PATIENTS WITH NEWLY DIAGNOSED GRADE III GLIOMAS WITHOUT 1p/19q CO-DELETION: A RANDOMIZED, OPEN-LABEL, PHASE 2 STUDY (INTERIM RESULTS FROM THE KNOG-1101 STUDY)

Chae-Yong Kim, Kihwan Hwang, Tae Min Kim, Chul-Kee Park, Jong Hee Chang, Tae-Young Jung, Dong-Eun Lee, Jungnam Joo, Ghee Young Choe, Yu Jung Kim, Byung Se Choi, Jeong Hoon Kim

Neuro-Oncology. 2018;20(suppl_6):vi23-vi23

Link1

Concurrent and Adjuvant Temozolomide for Newly Diagnosed Grade III Gliomas without 1p/19q Co-deletion: A Randomized, Open-Label, Phase 2 Study (KNOG-1101 Study)

Cancer Research and Treatment. 2020;52(2):505-515

Link1

Link2 Link3

SYST-10 CSNO2012001 STUDY: A PHASE III TRIAL ON ADJUVANT TEMOZOLOMIDE CHEMOTHERAPY WITH OR WITHOUT INTERFERON-ALPHA IN NEWLY DIAGNOSED HIGH-GRADE GLIOMAS

Zhongping Chen, Chengcheng Guo

Neuro-Oncology Advances. 2022;4(Supplement_1):i23-i23

Link1

Link2

CTNI-33. CSNO2012001 STUDY: A PHASE III TRIAL ON ADJUVANT TEMOZOLOMIDE CHEMOTHERAPY WITH OR WITHOUT INTERFERON-ALPHA IN NEWLY DIAGNOSED HIGH-GRADE GLIOMAS

ZhongPing Chen, Chengcheng Guo, JianGen Chen

Neuro-Oncology. 2022;24(Supplement_7):vii78-vii78

Link1

Link2

Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma

Binghao Zhao, Wenbin Ma

The Lancet Oncology. 2021;22(8):e345

Link1 Link2

Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma – Authors' reply

Martin J van den Bent, Mircea Tesileanu

The Lancet Oncology. 2021;22(8):e346

Link1 Link2

CTNI-42. PHASE I STUDY OF RUXOLITINIB WITH RADIATION AND TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED GRADE III GLIOMAS AND GLIOBLASTOMA

Yasmeen Rauf, Rachel Hufsey, Kathy robinson, John Suh, Samuel Chao, Erin Murphy, Jennifer Yu, David Peereboom, Manmeet Ahluwalia

Neuro-Oncology. 2021;23(Supplement_6):vi69-vi69

Link1

Link2

CTNI-41. PHASE I STUDY OF RUXOLITINIB WITH RADIATION AND TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED GRADE III GLIOMAS AND GLIOBLASTOMA

Yasmeen Rauf, Rachel Hufsey, Kathy Robinson, John Suh, Samuel Chao, Erin Murphy, Jennifer Yu, David Peereboom, Manmeet Ahluwalia

Neuro-Oncology. 2020;22(Supplement_2):ii51-ii51

Link1

Link2

Adjuvant Melatonin for Uveal Melanoma (AMUM): Protocol for a Randomized Open-label Phase III Study

Anna Hagström, UG Ruba Kal Omar, Stålhammar

. 2022;

Link1 Link2

Characterisation of isocitrate dehydrogenase gene mutant WHO grade 2 and 3 gliomas: MRI predictors of 1p/19q co-deletion and tumour grade

D. Doig, C. Kachramanoglou, M. Dumba, F. Tona, A. Gontsarova, C. Limbäck, W. Jan

Clinical Radiology. 2021;76(10):785.e9-785.e16

Link1 Link2

This metadata service is kindly provided by CrossRef from May 29, 2014. Cancer Res Treat has participated in CrossRef Text and Data Mining service since October 29, 2014.